These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19639352)

  • 1. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
    Willis M; Persson U; Zoellner Y; Gradl B
    Appl Health Econ Health Policy; 2010; 8(6):377-86. PubMed ID: 21043539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
    Jardin M; Cortaredona S; Bocquier A; Nauleau S; Sciortino V; Bouvenot J; Sauze L; Bouvenot G; Verger P
    Rev Epidemiol Sante Publique; 2011 Apr; 59(2):115-22. PubMed ID: 21435807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
    Persson U; Svensson J; Pettersson B
    Appl Health Econ Health Policy; 2012 Jul; 10(4):217-25. PubMed ID: 22676213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of health economic evaluations in Sweden.
    Heintz E; Arnberg K; Levin LÅ; Liliemark J; Davidson T
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):375-82. PubMed ID: 25444295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.
    Hawkins N; Scott DA
    Health Econ; 2011 Jun; 20(6):688-98. PubMed ID: 20568075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of rimonabant in the treatment of obesity.
    Hampp C; Hartzema AG; Kauf TL
    Value Health; 2008; 11(3):389-99. PubMed ID: 18179661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness.
    Svensson M; Nilsson FO; Arnberg K
    Pharmacoeconomics; 2015 Nov; 33(11):1229-36. PubMed ID: 26093889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement.
    Verger P; Rolland S; Paraponaris A; Bouvenot J; Ventelou B
    Fundam Clin Pharmacol; 2010 Aug; 24(4):509-16. PubMed ID: 19840120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.